PubMed HealthSearch

PubMed · 9782010

Pseudomyxoma peritonei.

Abstract

BACKGROUND: Pseudomyxoma peritonei is an unusual condition in which gelatinous fluid collections are associated with mucinous implants on the peritoneal surfaces and omentum. The pathological origin and ideal treatment of the condition are subjects of debate. METHODS: An unrestricted Medline search over 1986-1997 was performed for pseudomyxoma peritonei. RESULTS AND CONCLUSIONS: There is increasing evidence that pseudomyxoma peritonei is a neoplastic condition which usually arises from a primary adenoma or adenocarcinoma of the appendix. Reported series include a spectrum of pathological lesions, from entirely benign ruptured mucocele to advanced carcinoma. This, and the rarity of the condition, limit the conclusions that can be drawn regarding its treatment and prognosis. Most authorities agree that a thorough surgical debulking should be made. In most cases this will be a difficult and time-consuming undertaking, possibly requiring cooperation between two or more specialists and consideration of delivering intraperitoneal adjuvant therapy during or immediately after surgery. Treatment therefore requires a planned approach with accurate preoperative assessment of the diagnosis and the extent of the condition. There is some largely anecdotal evidence in favour of intraperitoneal chemotherapy and radioisotope treatment. Ultraradical surgery, with heated intraoperative and further postoperative chemotherapy, is strongly advocated by one group but remains contentious. The majority of patients will eventually suffer recurrence. The 5-year survival rate ranges from 53 to 75 per cent, but outcomes vary widely between relatively benign and malignant subgroups.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

F L Hinson, N S Ambrose. 1998. Pseudomyxoma peritonei.. https://doi.org/10.1046/j.1365-2168.1998.00882.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

[Esophageal carcinoma: surgical treatment concepts; access and resectability].

The resectability of oesophageal cancer depends very much on the tumour's localisation and extent. Maintenance of a proximal safety margin of at least 5 cm, and closeness to the posterior tracheal wall, only rarely allow primary resection of high thoracic or intracervical oesophageal cancer above the bifurcation. A possible alternative in this situation is combined radiochemotherapy. If the tumour responds to this therapy and there are no distant metastases, secondary resection frequently remains possible. On the other hand, in the distal oesophagus below the tracheal bifurcation, without involvement of the bronchial system, primary resection is often possible, and in this case infiltrated contiguous structures such as the pericardium and the crura of the diaphragm can also be resected. The extent of the lymphadenectomy is controversial at present. However, as part of an en bloc resection it should today include at least complete dissection of the posterior mediastinum and the upper abdomen (2-field lymphadenectomy). Additional cervical lymphadenectomy (3-field lymphadenectomy) can be recommended in high intrathoracic and cervical oesophageal cancer despite high morbidity, since this reduces the rate of loco-regional recurrences and thus improves the long-term prognosis. Mortality following oesophageal resection probably ranges around 5% today. Postoperative morbidity remains relatively high at over 50%. A reduction in morbidity demands not only competent surgical management and intensive care, but also, in particular, improved selection of patients and their specific preoperative preparation.

Combined Modality Therapy